Get started
Author

Marika Vianello

Observed names: M VIANELLO, M Vianello, M. Vianello, MARIKA VIANELLO, Vianello, Marika
ORCID: 0009-0006-0864-7230
Observed ORCID: 0009-0006-0864-7230
OpenAlex ID: A5108147029
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
2022 · Emilio Portaccio, Angelo Bellinvia, et al. · Brain · 182
PDF
Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis
2009 · M. Trojano, F. Pellegrini, et al. · Annals of Neurology · 149
PDF
Glutamic acid decarboxylase autoantibodies and neurological disorders
2002 · M. Vianello, B. Tavolato, et al. · Neurological Sciences · 93
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
2020 · Maria Pia Amato, Mattia Fonderico, et al. · Brain · 90
PDF
COVID-19 Severity in Multiple Sclerosis
2021 · Maria Pia Sormani, Irene Schiavetti, et al. · Neurology Neuroimmunology & Neuroinflammation · 75
PDF
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
2021 · Damiano Baroncini, Marta Simone, et al. · JAMA Neurology · 63
PDF
Multiple Sclerosis Progression and Relapse Activity in Children
2023 · Pietro Iaffaldano, Emilio Portaccio, et al. · JAMA Neurology · 51
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
2021 · Maria Pia Sormani, Irene Schiavetti, et al. · Multiple Sclerosis Journal · 47
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries
2024 · Sifat Sharmin, Izanne Roos, et al. · The Lancet Child & Adolescent Health · 42
The spectrum of antineuronal autoantibodies in a series of neurological patients
2004 · M Vianello, R Vitaliani, et al. · Journal of the Neurological Sciences · 42
Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies
2003 · M Vianello, B Tavolato, et al. · The Cerebellum · 42
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
2024 · Emilio Portaccio, Matteo Betti, et al. · Journal of Neurology · 39
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment
2009 · M. Trojano, F. Pellegrini, et al. · Journal of the Neurological Sciences · 28
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis
2024 · Pietro Iaffaldano, Giuseppe Lucisano, et al. · Annals of Clinical and Translational Neurology · 25
Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association
2005 · Sandra Piquer, Cristina Belloni, et al. · Clinical Immunology · 24
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis
2024 · Marta Simone, Giuseppe Lucisano, et al. · Journal of Neurology · 21
PDF
X‐linked adrenoleukodystrophy with olivopontocerebellar atrophy
2005 · M. Vianello, R. Manara, et al. · European Journal of Neurology · 21
Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis
2022 · Ermelinda De Meo, Massimo Filippi, et al. · Annals of Neurology · 20
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
2021 · Emanuele D'Amico, Aurora Zanghì, et al. · Neurotherapeutics · 20
PDF
Encephalitis associated with glutamic acid decarboxylase autoantibodies
2001 · G.C. Marchiori, A. Vaglia, et al. · Neurology · 20
Virtual visits for chronic neurologic disorders during COVID-19 pandemic
2021 · Irene Rosellini, Marika Vianello, et al. · Neurological Sciences · 19
PDF
Peculiar labeling of cultured hippocampal neurons by different sera harboring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab)
2006 · M VIANELLO, B GIOMETTO, et al. · Experimental Neurology · 19
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
2022 · Emilio Portaccio, Mattia Fonderico, et al. · JAMA Neurology · 16
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
2021 · Clara G. Chisari, Giancarlo Comi, et al. · Journal of Neurology · 16
Tremor of the mouth floor and anti‐glutamic acid decarboxylase autoantibodies
2003 · M. Vianello, F. Morello, et al. · European Journal of Neurology · 16
Works count: 60
Citation count: 1,331
H-index: 20
I10-index: 30
Year
Topic
Type